A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
|Articles|November 3, 2014
The One Device I Can't Live Without
In your practice, what is the one piece of technology you can’t live without and why? Vegas Cosmetic Surgery 2014 Laser Roundtable experts Grant Stevens, M.D., Berry DiBernardo, M.D., Jason Pozner, M.D., David Goldberg, M.D., J.D., Michael Gold, M.D., Jill Waibel, M.D., A. Jay Burns, M.D., and E. Victor Ross, M.D., share their answers.
Advertisement
In your practice, what is the one piece of technology you can’t live without and why? Vegas Cosmetic Surgery 2014 Laser Roundtable experts Grant Stevens, M.D., Berry DiBernardo, M.D., Jason Pozner, M.D., David Goldberg, M.D., J.D., Michael Gold, M.D., Jill Waibel, M.D., A. Jay Burns, M.D., and E. Victor Ross, M.D., share their answers.
Advertisement
Related to this article
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
3
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
4
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
5